SecBot SecBot
8-K ·Filed Nov 10, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 5/10
Horizonmonths Processed6d 11h ago SEC0001055726-26-000030
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The earnings release confirms the capital need that drove the $75M dilutive offering 4 days prior. Watch for VOCERYQ launch execution in Q1 2027 and the confirmatory study protocol submission by year-end 2026. The cash runway projection excludes any VOCERYQ revenue, so first commercial sales will be critical for extending the timeline beyond late 2027.

DirectionBearish
Confidencehigh
Horizonmonths

Drug in focus

INO drug pipeline →

VOCERYQ

● Neutral Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
Next catalyst
None dated

What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.48
T+0 close · Nov 10, 2026 · via day close
Latest settled
−1.02%
T+1 · $1.46
Vs SPY
−0.66%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $1.48entry
  2. T+1 · 5d ago −1.02%α −0.66% · $1.46
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cash stood at $48.4M pre-offering, with $80.5M in net proceeds from the November 2026 offering extending runway into late Q4 2027. The FDA accelerated approval of VOCERYQ on October 30 positions the company for its first commercial launch, but the massive dilutive offering (53% of pre-offering shares) and continued operating losses weigh heavily.

Key Financial Metrics

Revenue
$298.9K
est $0.00

Key Facts

  • Q3 2026 net loss of $49.2M vs $45.5M in Q3 2025, driven by $26.9M non-cash warrant liability adjustment
  • Cash, cash equivalents and short-term investments of $48.4M as of September 30, 2026, down from $58.5M at year-end 2025
  • Net proceeds of $80.5M from November 2026 public offering extend cash runway into late Q4 2027
  • FDA granted accelerated approval for VOCERYQ on October 30, 2026; commercial launch expected Q1 2027
  • Operating expenses decreased to $19.8M from $21.2M year-over-year, with R&D down and SG&A up
  • Weighted average diluted shares outstanding of 98.6M in Q3 2026, nearly double the 52.2M in Q3 2025
  • Stockholders' equity negative $33.9M as of September 30, 2026, vs positive $24.1M at year-end 2025

Financial Impact

Q3 net loss $49.2M; cash burn continues; $80.5M offering proceeds provide runway into late Q4 2027

net losscashdilutionstockholders equity

Risk Factors

  • Massive dilution from the November 2026 offering (53% of pre-offering shares) at a deep discount
  • Negative stockholders' equity of $33.9M and going concern risk remain despite the capital raise
  • VOCERYQ commercial launch is unproven; revenue may not materialize as expected
  • Continued approval of VOCERYQ is contingent on a confirmatory study, with protocol alignment not expected until mid-2027
  • Warrant liability fair value adjustments create significant earnings volatility tied to stock price

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001055726-26-000030
Document: ino-20261110.htm0001055726-26-000030
Document: 0001055726-26-000030-index-headers.html0001055726-26-000030
Document: 0001055726-26-000030-index.html0001055726-26-000030
Document: 0001055726-26-000030.txt0001055726-26-000030
8-K Data (Synthetic)0001055726-26-000030

Track record

20 reports on INO

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Viewing Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026